Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday.

According to Zacks, “Aeglea BioTherapeutics, Inc. is a biotechnology company which is engaged in developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. Its portfolio of products consists of AEB1102, AEB3103, AEB2109 and AEB4104 which are in different clinical trial phase. Aeglea BioTherapeutics, Inc. is based in Austin, Texas. “

AGLE has been the topic of several other reports. ValuEngine raised shares of Aeglea BioTherapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. TheStreet downgraded shares of Aeglea BioTherapeutics from a “c-” rating to a “d+” rating in a research report on Friday, May 26th.

Aeglea BioTherapeutics (AGLE) traded down 2.16% on Tuesday, reaching $4.54. 17,019 shares of the company traded hands. The company’s market capitalization is $74.69 million. Aeglea BioTherapeutics has a one year low of $2.81 and a one year high of $10.34. The stock’s 50 day moving average price is $3.60 and its 200 day moving average price is $5.00.

COPYRIGHT VIOLATION WARNING: “Aeglea BioTherapeutics, Inc. (AGLE) Lowered to “Hold” at Zacks Investment Research” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/09/19/aeglea-biotherapeutics-inc-agle-lowered-to-hold-at-zacks-investment-research.html.

A number of hedge funds have recently made changes to their positions in AGLE. Bank of New York Mellon Corp purchased a new stake in Aeglea BioTherapeutics during the 1st quarter valued at about $157,000. Renaissance Technologies LLC purchased a new stake in Aeglea BioTherapeutics during the 1st quarter valued at about $270,000. Vanguard Group Inc. grew its position in Aeglea BioTherapeutics by 9.4% during the 2nd quarter. Vanguard Group Inc. now owns 150,774 shares of the biotechnology company’s stock valued at $579,000 after purchasing an additional 12,966 shares during the last quarter. Finally, Susquehanna International Group LLP purchased a new stake in Aeglea BioTherapeutics during the 2nd quarter valued at about $653,000. 48.10% of the stock is currently owned by institutional investors.

About Aeglea BioTherapeutics

Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.

Get a free copy of the Zacks research report on Aeglea BioTherapeutics (AGLE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aeglea BioTherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.